Figure 6. Administration of a second booster dose further
enhances antibody response and neutralization capacity of
mCuMVTT-RBM
A, Vaccination regimen D0/28 or D0/28/D49 and bleeding schedule. B,
RBD-specific IgG titer for the groups vaccinated with
mCuMVTT-RBM vaccine candidate on day 14 (after prime),
day 42 (after 2nd dose) and day 63 (after
3rd dose) measured by ELISA OD450. C,
Log OD50 of RBD-specific IgG titer for the groups
vaccinated with mCuMVTT-RBM vaccine candidate on day 14
(after prime), day 42 (after 2nd dose) and day 63
(after 3rd dose) (Data from B). D, Avidity of
RBD-specific IgG titer in mice vaccinated with
mCuMVTT-RBM on day 42 (after 2nd dose)
and day 63 (after 3rd dose) measured by ELISA
OD450, sera were treated with PBST or 7M Urea. E, Log
OD50 of RBD-specific IgG titer in mice vaccinated with
mCuMVTT-RBM on day 42 (after 2nd dose)
and day 63 (after 3rd dose) (data from D). F,
Neutralization titer (CPE) for sera from CuMVTT control
group, day 42 (after 2nd dose) and day 63 (after
3rd dose). Statistical analysis (mean ± SEM) usingStudents t-test , n=5 . One representative of 2 similar
experiments is shown. The value of p<0.05 was considered
statistically significant (*p <0.01,
**p <0.001, ***p <0.0001).